Abstract:Background: Fresh frozen plasma (FFP) is exposed to numerous factors affecting the quality and stability of coagulation factors during blood collection, preparation and storage. In 1995 the European ‘Guide to the preparation, use and quality assurance of blood components’ extended the shelf-life of FFP from 12 to 24 months and concurrently reduced the storage temperature from –30 to –40 °C. Four years later, the European guidelines amended the storage regulations and permitted a 24-month shelf-life at –30 °C. This new regulation of FFP led us to the question whether storage over 3 years at –40 °C could be performed without relevant loss in coagulation factor activity. Due to missing data, a multicenter study was carried out in 7 different quality control (QC) laboratories of the Bavarian Red Cross Blood Transfusion Service. The aim of our study was to obtain selected stability data of the coagulation factors FV, FVIII:C and FXI as well as of the major inhibitor antithrombin III (AT III) over a storage period of more than 3 years at –40 °C. Material and Methods: 12 plasma units – 3 of each ABO blood group – derived from CPD whole blood were processed according to current national and European guidelines. The plasma units were aliquoted and frozen within 18 h after donation at below –30 °C. The storage temperature was held between –38 and –42 °C during the total storage period of 37 months. In the long-term storage, 4 parameters of the coagulation system were determined in aliquots in 7 different QC laboratories. One-stage coagulometric methods were used to determine coagulation factors, and the determination of AT III inhibitor activity was done by a chromogenic method. After the 1st month of storage, each plasma was tested for specific activity. Thereafter, follow-up testing was performed in 4-month periods. Results: The evaluated coagulation parameters show an acceptable stability during the total storage period if ABO blood groups are not taken into consideration. There was no statistically significant loss in activity for FXI and AT III at the end of the storage period in comparison to the initial values, 101.5% for FXI (pFXI = 0.17) and 101% for AT III (pAT III = 0.66). The loss in FV and in FVIII:C activities was 0.6 and 9%, respectively. Both results indicate a statistically significant reduction (t test: pFV = 0.048; pFVIII:C = 0.033). Similar results were obtained taking ABO blood grouping into account, with the exceptions of blood group A where AT III showed an increase of 11% over baseline values and of blood group O where FXI showed an increase of 11.2% over average coagulation activities. There were no differences in the coagulation activities of blood groups B and AB over the storage period. Conclusions: The results show that, under these storage conditions, the recovery of coagulation parameters in FFP is not reduced below 70% of the starting activity and stays in acceptable ranges. For FXI and AT III we did not find any significant reduction. However, for FV and FVIII:C a significant reduction was found, although total activities were not dramatically low. With regard to the guidelines for therapeutic plasma, our findings show that an extended storage for up to 3 years at –40 °C should be possible without clinically relevant loss of efficacy.

In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto) stability during simulated continuous infusion administration

A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards

Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations

Transmissible spongiform encephalopathy agent clearance by the immunoaffinity and anion-exchange chromatography steps of the ReFacto manufacturing process

Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients

Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A

Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay

Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves

Recombinant factor IX Fc for the treatment of hemophilia B

Long-Term Storage of Fresh Frozen Plasma at –40 °C. A Multicenter Study on the Stability of Labile Coagulation Factors over a Period of 3 Years

Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans